| Under the agreement, the Tata group company will conduct offshore clinical operation services for Novo Nordisk in India and offer a slew of data management services. | |
| The size of the deal could not be ascertained. Industry sources said this could be a multi-million dollar deal over a period of time, as the global outsourcing of clinical trial management is estimated at around $1 billion over the next five-year period. | |
| Confirming the news, executive vice-president and head (Global Life Sciences and Healthcare Practice) J Rajgopal said, "This could be one of the first outsourcing deals, in the clinical trial-data management space, for an Indian company". | |
| He added: "The deal is strategic in nature, as it gives our company an opportunity to leverage our domain capability and provide our products, solutions and services across the pharma value chain." | |
| He, however, did not divulge the size of the deal. TCS plans to implement offshore clinical operations services from its Mumbai centre and offer a slew of data management services, such as designing, capturing and coding of trial-data, gathered by Novo Nordisk from across the world. | |
| Earlier this year, TCS had entered into an agreement with Congenia, a biotechnology start-up promoted by Italy's Genextra SpA group, to provide advanced fragment-based lead optimisation solutions for drug discovery. | |
| TCS will work on "P66" "" a target protein identified by Congenia as a key protein involved in several age-related diseases "" and develop optimised drug leads based on this. | |
| TCS is focussing on the life-science sector, as an engine of growth and is expecting to post revenues of 50 per cent growth over the next few years. TCS is also close to tying-up with other pharma majors across the world for similar kind of deals. However, Rajgopal did not divulge the name of the companies, the company was in talks with.
| |
Top Section
Explore Business Standard